The popularity of Sildenafil initially drove a period of growth for the drug industry, but recent changes present a murky outlook for those considering a stake. Generic versions are eroding revenue, and persistent legal battles add more complexity to the equation. While specific companies may still benefit from related offerings, the overall direct